Upstream Bio Inc.
Clinical trials sponsored by Upstream Bio Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New asthma drug verekitug tested for Long-Term safety Results expected Sep 2027 (estimated)
-
Can an antibody injection shrink nasal polyps?
Disease control CompletedResearchers are testing an experimental antibody drug called verekitug in adults with chronic rhinosinusitis with nasal polyps, a condition where inflamed tissue grows inside the nasal passages and causes congestion. Participants receive either verekitug or a placebo injection wh…
Phase 2 • Sponsor: Upstream Bio Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug verekitug aims to curb severe asthma attacks
Disease control CompletedThis study tested a new drug called verekitug (UPB-101) in 479 adults with severe asthma. The goal was to see if it could reduce asthma attacks and improve lung function compared to a placebo. Participants received either verekitug or a dummy injection over several months. The tr…
Phase 2 • Sponsor: Upstream Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC